Immunize

Respiratory Syncytial Virus Vaccine

search

Respiratory Syncytial Virus Vaccine, RSV Vaccine, Palivizumab, Synagis

  • Mechanism
  1. Humanized mouse Monoclonal Antibody to RSV
  • Indications
  • Based on AAP guidelines
  1. Chronic lung disease in age <2 years
    1. Medication treatment within 6 months of RSV season start
  2. Hemodynamically significant Congenital Heart Disease in age <2 years
  3. Consider in infants with severe Immunodeficiency
  4. Preterm Infants during their first RSV season
    1. Gestational age at birth <28 weeks (Give during first RSV season)
    2. Gestational age at birth 28-32 weeks who are under age 6 months during RSV season
    3. Gestational age 32-35 weeks with 2 risk factors:
      1. Day care attendance
      2. Siblings under 5 years of age
      3. Congenital airway abnormality
      4. Congenital neuromuscular disease
  • Dosing
  1. Palivizumab 1 dose IM monthly for 5 months of RSV season (November 1 to March 1)
  • Efficacy
  1. Decreases hospitalizations by 45 to 55%
  • References
  1. Pickering (2009) Red Book, AAP, Elk Grove Village, p. 560